James Turkson

USPTO Granted Patents = 27 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 35(Granted Patents)

Location History:

Tampa, FL (US) (2007 - 2010)
Orlando, FL (US) (2010 - 2019)
Honolulu, HI (US) (2017 - 2023)

Company Filing History:

17 out of 1,309

University of Central Florida Research Foundation, Inc.

patents

12 out of 1,929

University of South Florida

patents

7 out of 290

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

4. 4 out of 493

The Governing Council of the University of Toronto

University of Hawai'i

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11571418 - Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells (2023-02-07),

2. 11299480 - 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors (2022-04-12),

3. 10813927 - Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells (2020-10-27),

4. 10806712 - Small molecule inhibitors of STAT3 with anti-tumor activity (2020-10-20),

5. 10800790 - Sesquiterpenoid STAT3 inhibitors (2020-10-13),

6. 10226439 - Small molecule inhibitors of STAT3 with anti-tumor activity (2019-03-12),

7. 10196373 - Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein (2019-02-05),

8. 9968599 - Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells (2018-05-15),

9. 9802888 - STAT3 inhibitors (2017-10-31),

10. 9604923 - Small molecule inhibitors of STAT3 with anti-tumor activity (2017-03-28),

11. 9504761 - Stabilized chitosan-based nanoparticles and methods for making the same (2016-11-29),

12. 9474809 - Activatable nanoprobes for intracellular drug delivery (2016-10-25),

13. 8969578 - Inhibitors of STAT3 (2015-03-03),

14. 8895746 - Compounds that suppress cancer cells and exhibit antitumor activity (2014-11-25),

15. 8846707 - Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein (2014-09-30),

Title: James Turkson: Innovator in Oncology Research

Introduction

James Turkson is a prominent inventor based in Orlando, FL, known for his significant contributions to oncology research. With an impressive portfolio of 27 patents, Turkson has dedicated his career to developing novel compounds that target cancer pathways, resulting in potential therapeutic advancements.

Latest Patents

Among his latest works, Turkson has patented several groundbreaking inventions, including a series of platinum compounds that inhibit the constitutive STAT3 signaling pathway. His invention promotes cell cycle arrest and apoptosis of malignant cells, highlighting the potential for targeted cancer treatments. Another notable patent involves 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors, which offer pharmaceutical compositions that enhance the efficacy of cancer therapies, along with methods for their application.

Career Highlights

Throughout his career, Turkson has been associated with prestigious research institutions. He has held significant positions at the University of Central Florida Research Foundation and the University of South Florida, where his research has focused on the development of innovative therapeutic strategies against cancer.

Collaborations

Turkson's collaborative work includes partnerships with esteemed researchers, such as Said M. Sebti and Richard Jove. These collaborations have contributed to the depth and impact of his research, allowing for a multidisciplinary approach in addressing complex cancer treatment challenges.

Conclusion

James Turkson's work exemplifies the intersection of innovation and dedication within the field of cancer research. His numerous patents and collaborations underscore his commitment to finding effective treatments that may one day improve patient outcomes in oncology. As his research continues to evolve, the scientific community anticipates further breakthroughs that could reshape cancer therapeutics.

This text is generated by artificial intelligence and may not be accurate.